New tuberculosis drug development: Targeting the shikimate pathway

Expert Opinion on Drug Discovery

Volumn 3, Issue 5, 2008, Pages 565-577

  Kapnick, Senta M ^a   Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Drug development; Mycobacterium tuberculosis; Shikimate kinase; Shikimate pathway

Indexed keywords

1,3,4 TRIHYDROXYCYLOHEX 5 EN 1 CARBOXYLIC ACID DERIVATIVE; 3 DEHYDROQUINATE SYNTHASE; 3 DEOXY 7 PHOSPHOHEPTULONATE SYNTHASE; 3 METHOXY 4 [[2 [[ METHOXY 4 [(4 OXO 2 THIOXO 1,3 THIAZOLIDIN 5 YLIDENE)METHYL]PHENOXY]METHYL]BENZYL]OXY]BENZALDEHYDE; 3 PHOSPHOSHIKIMATE 1 CARBOXYVINYLTRANSFERASE; 5 BROMO 2 [5 [[1 (3,4 DICHLOROPHENYL) 3,5 DIOXO 4 PYRAZOLIDINYLIDENE]METHYL] 2 FURYL]BENZOIC ACID; 6 FLUOROSHIKIMIC ACID; AMIKACIN; ANTIINFECTIVE AGENT; AROMATIC AMINO ACID; BACTERIAL ENZYME; CAPREOMYCIN; CHORISMIC ACID; ENZYME INHIBITOR; ETHAMBUTOL; FOLIC ACID DERIVATIVE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; SHIKIMATE DEHYDROGENASE; SHIKIMATE ENZYME; SHIKIMIC ACID; STREPTOMYCIN; TUBERCULOSTATIC AGENT; VACCINE;

ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL METABOLISM; BIOSYNTHESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME SYNTHESIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHIKIMATE PATHWAY; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; VACCINE PRODUCTION;

EID: 44649177007     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.5.565     Document Type: Review

References (117)

1. Dubos R, Dubos J. The white plague: tuberculosis, man, and society. New Brunswick: Rutgers University Press; 1987
2. Bunyan J. The Life and Death of Mr. Badman. London: Hesperus Press; 2007
3. World Health Organization. The World Health Organization Global Tuberculosis Program. 2007. Available from: http://www.who.int/tb/en/
4. McShane H. Co-infection with HIV and TB: double trouble. Int J STD AIDS 2005;16:95-101
5. Oursler K, Moore R, Bishai W, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002;34:752-9
6. Elliot A, Halwiindi B, Hayes R, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 1995;89:78-82
7. Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987;136(3):570-4
8. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999;353(9167):1843-7
9. March F, Garriga X, Rodriguez P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997;25(5):1044-7
10. Frothingham R, Stout JE, Hamilton CD. Current issues in global tuberculosis control. Int J Infect Dis 2005;9(6):297-311
11. Sepkowitz KA, Raffalli J, Riley L, et al. Tuberculosis in the AIDS era. Clin Microbiol Rev 1995;8(2):180-99
12. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991;144(4):750-5
13. World Health Organization. Stop TB Partnership. 2007. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/index.html
14. Castro K. Extensively drug resistant TB (XDR-TB) late breaking update. CDC DTBE All Hands Meeting; 2006 October 15
15. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368(9547):1575-80
16. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005;171(7):699-706
17. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 1944;55:66-9
18. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-79
19. Waksman SA, Reilly HC, Schatz A. Strain specificity and production of antibiotic substances. V. Strain resistance of bacteria to antibiotic substances, especially to streptomycin. Proc Natl Acad Sci USA 1945;31(6):157-64
20. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9(10):2026-30
21. Awofesoa N. Anti-tuberculosis medication side-effects constitute a major factor for poor treatment adherence. Bulletin of the World Health Organization; 2006
22. Zhang Y. The magic bullets and tuberculosis drug targets. Ann Rev Pharmacol Toxicol 2005;45:529-64
23. Shah D, Zhang Z, Khodursky A, et al. Persisters: a distinct physiological state of E. coli. BMC Microbiol 2006;6:53
24. Massey RC, Buckling A, Peacock SJ. Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus. Curr Biol 2001;11(22):1810-4
25. Kussell E, Kishony R, Balaban NQ, et al. Bacterial persistence: a model of survival in changing environments. Genetics 2005;169(4):1807-14
26. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66(3):219-25
27. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007;82(5):595-600
28. Bigger J. Treatment of staphylococcal infections with penicillin. Lancet 1944;ii:497-500
29. Klapper I, Gilbert P, Ayati BP, et al. Senescence can explain microbial persistence. Microbiology 2007;153(Pt 11):3623-30
30. Miller C, Thomsen LE, Gaggero C, et al. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 2004;305(5690):1629-31
31. Balaban NQ, Merrin J, Chait R, et al. Bacterial persistence as a phenotypic switch. Science 2004;305(5690):1622-5
32. Byrne ST, Gu P, Zhou J, et al. Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51(12):4495-7
33. Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 2006;19(3):558-70
34. Korch SB, Henderson TA, Hill TM. Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol 2003;50(4):1199-213
35. Korch SB, Hill TM. Ectopic overexpression of wild-type and mutant hipA genes in Escherichia coli: effects on macromolecular synthesis and persister formation. J Bacteriol 2006;188(11):3826-36
36. Gerdes K, Rasmussen PB, Molin S. Unique type of plasmid maintenance function: postsegregational killing of plasmid-free cells. Proc Natl Acad Sci USA 1986;83(10):3116-20
37. Keren I, Shah D, Spoering A, et al. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 2004;186(24):8172-80
38. Vazquez-Laslop N, Lee H, Neyfakh AA. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J Bacteriol 2006;188(10):3494-7
39. Li Y, Zhang Y. PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob Agents Chemother 2007;51(6):2092-9
40. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393(6685):537-44
41. Duncan K. Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 2004;10(26):3185-94
42. Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 2002;148(Pt 10):3069-77
43. Ducati RG, Basso LA, Santos DS. Mycobacterial shikimate pathway enzymes as targets for drug design. Curr Drug Targets 2007;8(3):423-35
44. Starcevic A, Akthar S, Dunlap WC, et al. Enzymes of the shikimic acid pathway encoded in the genome of a basal metazoan, Nematostella vectensis, have microbial origins. Proc Natl Acad Sci USA 2008;105(7):2533-7
45. Bentley R. The shikimate pathway - a metabolic tree with many branches. Crit Rev Biochem Mol Biol 1990;25(5):307-84
46. Coggins J. The shikimate pathway as a target for herbicides. In: Dodge A, editor, Herbicides and plant metabolism. Cambridge: Cambridge University Press; 1989
47. Roberts F, Roberts CW, Johnson JJ, et al. Evidence for the shikimate pathway in apicomplexan parasites. Nature 1998;393(6687):801-5
48. Coggins JR, Abell C, Evans LB, et al. Experiences with the shikimate-pathway enzymes as targets for rational drug design. Biochem Soc Trans 2003;31(Pt 3):548-52
49. Davis BD. Aromatic biosynthesis. I. The role of shikimic acid. J Biol Chem 1951;191(1):315-25
50. Davis BD, Mingioli ES. Aromatic biosynthesis. VII. Accumulation of two derivatives of shikimic acid by bacterial mutants. J Bacteriol 1953;66(2):129-36
51. Srinivasan PR, Shigeura HT, Sprecher M, et al. The biosynthesis of shikimic acid from D-glucose. J Biol Chem 1956;220(1):477-97
52. Garbe T, Jones C, Charles I, et al. Cloning and characterization of the aroA gene from Mycobacterium tuberculosis. J Bacteriol 1990;172(12):6774-82
53. Srinivasan PR, Rothschild J, Sprinson DB. The enzymic conversion of 3-deoxy-D-arabino-heptulosonic acid 7-phosphate to 5-dehydroquinate. J Biol Chem 1963;238:3176-82
54. Mitsuhashi S, Davis BD. Aromatic biosynthesis. XII. Conversion of 5-dehydroquinic acid to 5-dehydroshikimic acid dy 5-dehydroquinase. Biochem Biophys Acta 1954;15(1):54-61
55. Yaniv H, Gilvarg C. Aromatic biosynthesis. XIV. 5-Dehydroshikimic reductase. J Biol Chem 1955;213(2):787-95
56. Pereira JH, Vasconcelos IB, Oliveira JS, et al. Shikimate kinase: a potential target for development of novel antitubercular agents. Curr Drug Targets 2007;8(3):459-68
57. Levin JG, Sprinson DB. The enzymatic formation and isolation of 3-enolpyruvylshikimate 5-phosphate. J Biol Chem 1964;239:1142-50
58. Oliveira JS, Pinto CA, Basso LA, et al. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif 2001;22(3):430-5
59. Pereira JH, de Oliveira JS, Canduri F, et al. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid. Acta Crystallogr D Biol Crystallogr 2004;60(Pt 12 Pt 2):2310-9
60. Dhaliwal B, Nichols CE, Ren J, et al. Crystallographic studies of shikimate binding and induced conformational changes in Mycobacterium tuberculosis shikimate kinase. FEBS Lett 2004;574(1-3):49-54
61. Lobner-Olesen A, Marinus MG. Identification of the gene (aroK) encoding shikimic acid kinase I of Escherichia coli. J Bacteriol 1992;174(2):525-9
62. Millar G, Lewendon A, Hunter MG, et al. The cloning and expression of the aroL gene from Escherichia coli K12. Purification and complete amino acid sequence of shikimate kinase II, the aroL-gene product. Biochem J 1986;237(2):427-37
63. DeFeyter RC, Pittard J. Purification and properties of shikimate kinase II from Escherichia coli K-12. J Bacteriol 1986;165(1):331-3
64. Ely B, Pittard J. Aromatic amino acid biosynthesis: regulation of shikimate kinase in Escherichia coli K-12. J Bacteriol 1979;138(3):933-43
65. Weiss U, Edwards J. The biosynthesis of aromatic compounds. New York: John Wiley and Sons; 1980
66. An M, Toochinda T, Bartlett PA. Five-membered ring analogues of shikimic acid. J Org Chem 2001;66(4):1326-33
67. Gu Y, Reshetnikova L, Li Y, et al. Crystallization and preliminary X-ray diffraction analysis of shikimate kinase from Mycobacterium tuberculosis in complex with MgADP. Acta Crystallogr D Biol Crystallogr 2001;57(Pt 12):1870-1
68. Gu Y, Reshetnikova L, Li Y, et al. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of the LID domain in catalysis. J Mol Biol 2002;319(3):779-89
69. Dias MV, Faim LM, Vasconcelos IB, et al. Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007;63(Pt 1):1-6
70. Hartmann MD, Bourenkov GP, Oberschall A, et al. Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis. J Mol Biol 2006;364(3):411-23
71. Matte A, Tari LW, Delbaere LT. How do kinases transfer phosphoryl groups? Structure 1998;6(4):413-9
72. Vonrhein C, Schlauderer GJ, Schulz GE. Movie of the structural changes during a catalytic cycle of nucleoside monophosphate kinases. Structure 1995;3(5):483-90
73. Walker JE, Saraste M, Runswick MJ, et al. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982;1(8):945-51
74. Smith CA, Rayment I. Active site comparisons highlight structural similarities between myosin and other P-loop proteins. Biophys J 1996;70(4):1590-602
75. Leipe DD, Koonin EV, Aravind L. Evolution and classification of P-loop kinases and related proteins. J Mol Biol 2003;333(4):781-815
76. Brown J, Warren P. Antibiotic discovery: is it all in the genes? Drug Discov Today 1998;3:564-66
77. Davies GM, Barrett-Bee KJ, Jude DA, et al. (6S)-6-fluoroshikimic acid, an antibacterial agent acting on the aromatic biosynthetic pathway. Antimicrob Agents Chemother 1994;38(2):403-6
78. Bornemann S, Ramjee MK, Balasubramanian S, et al. Escherichia coli chorismate synthase catalyzes the conversion of (6S)-6-fluoro-5-enolpyruvylshikimate-3-phosphate to 6-fluorochorismate. Implications for the enzyme mechanism and the antimicrobial action of (6S)-6-fluoroshikimate. J Biol Chem 1995;270(39):22811-5
79. Green JM, Merkel WK, Nichols BP. Characterization and sequence of Escherichia coli pabC, the gene encoding aminodeoxychorismate lyase, a pyridoxal phosphate-containing enzyme. J Bacteriol 1992;174(16):5317-23
80. Jude DA, Ewart CD, Thain JL, et al. Transport of the antibacterial agent (6S)-6-fluoroshikimate and other shikimate analogues by the shikimate transport system of Escherichia coli. Biochim Biophys Acta 1996;1279(2):125-9
81. Ewart CD, Jude DA, Thain JL, et al. Frequency and mechanism of resistance to antibacterial action of ZM 240401, (6S)-6-fluoro-shikimic acid. Antimicrob Agents Chemother 1995;39(1):87-93
82. Rizzi C, Frazzon J, Ely F, et al. DAHP synthase from Mycobacterium tuberculosis H37Rv: cloning, expression, and purification of functional enzyme. Protein Expr Purif 2005;40(1):23-30
83. Magalhaes ML, Pereira CP, Basso LA, et al. Cloning and expression of functional shikimate dehydrogenase (EC 1.1.1.25) from Mycobacterium tuberculosis H37Rv. Protein Expr Purif 2002;26(1):59-64
84. Zhang X, Zhang S, Hao F, et al. Expression, purification and properties of shikimate dehydrogenase from Mycobacterium tuberculosis. J Biochem Mol Biol 2005;38(5):624-31
85. Oliveira JS, Mendes MA, Palma MS, et al. One-step purification of 5-enolpyruvylshikimate-3-phosphate synthase enzyme from Mycobacterium tuberculosis. Protein Expr Purif 2003;28(2):287-92
86. de Mendonca JD, Ely F, Palma MS, et al. Functional characterization by genetic complementation of aroB-encoded dehydroquinate synthase from Mycobacterium tuberculosis H37Rv and its heterologous expression and purification. J Bacteriol 2007;189(17):6246-52
87. Garbe T, Servos S, Hawkins A, et al. The Mycobacterium tuberculosis shikimate pathway genes: evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases. Mol Gen Genet 1991;228(3):385-92
88. Dias MV, Borges JC, Ely F, et al. Structure of chorismate synthase from Mycobacterium tuberculosis. J Struct Biol 2006;154(2):130-43
89. Shumilin IA, Kretsinger RH, Bauerle RH. Crystal structure of phenylalanine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Escherichia coli. Structure 1999;7(7):865-75
90. Webby CJ, Lott JS, Baker HM, et al. Crystallization and preliminary X-ray crystallographic analysis of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005;61(Pt 4):403-6
91. Gourley DG, Shrive AK, Polikarpov I, et al. The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction. Nat Struct Biol 1999;6(6):521-5
92. Frederickson M, Parker EJ, Hawkins AR, et al. Selective inhibition of type II dehydroquinases. J Org Chem 1999;64(8):2612-3
93. Sanchez-Sixto C, Prazeres VF, Castedo L, et al. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase. J Med Chem 2005;48(15):4871-81
94. Filgueira de Azevedo W Jr, Canduri F, Simoes de Oliveira J, et al. Molecular model of shikimate kinase from Mycobacterium tuberculosis. Biochem Biophys Res Commun 2002;295(1):142-8
95. Han C, Zhang J, Chen L et al. Discovery of Helicobacter pylori shikimate kinase inhibitors: bioassay and molecular modeling. Bioorg Med Chem 2007;15(2):656-62
96. Marques MR, Pereira JH, Oliveira JS, et al. The inhibition of 5-enolpyruvylshikimate-3-phosphate synthase as a model for development of novel antimicrobials. Curr Drug Targets 2007;8(3):445-57
97. Dias MV, Ely F, Palma MS, et al. Chorismate synthase: an attractive target for drug development against orphan diseases. Curr Drug Targets 2007;8(3):437-44
98. Smith DA, Parish T, Stoker NG, et al. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001;69(2):1142-50
99. Hondalus MK, Bardarov S, Russell R, et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 2000;68(5):2888-98
100. Hoiseth SK, Stocker BA. Genes aroA and serC of Salmonella typhimurium constitute an operon. J Bacteriol 1985;163(1):355-61
101. Dilts DA, Riesenfeld-Orn I, Fulginiti JP, et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000;18(15):1473-84
102. Stritzker J, Janda J, Schoen C, et al. Growth, virulence, and immunogenicity of Listeria monocytogenes aro mutants. Infect Immun 2004;72(10):5622-9
103. Cersini A, Salvia AM, Bernardini ML. Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants. Infect Immun 1998;66(2):549-57
104. Scott PC, Markham JF, Whithear KG. Safety and efficacy of two live Pasteurella multocida aro-A mutant vaccines in chickens. Avian Dis 1999;43(1):83-8
105. Fittipaldi N, Harel J, D'Amours B, et al. Potential use of an unencapsulated and aromatic amino acid-auxotrophic Streptococcus suis mutant as a live attenuated vaccine in swine. Vaccine 2007;25(18):3524-35
106. Marsden MJ, Vaughan LM, Fitzpatrick RM, et al. Potency testing of a live, genetically attenuated vaccine for salmonids. Vaccine 1998;16(11-12):1087-94
107. Stocker BA. Auxotrophic Salmonella typhi as live vaccine. Vaccine 1988;6(2):141-5
108. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003;6(5):427-30
109. Carpenter EP, Hawkins AR, Frost JW, et al. Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis. Nature 1998;394(6690):299-302
110. Widlanski T, Bender SL, Knowles JR. Dehydroquinate synthase: the use of substrate analogues to probe the late steps of the catalyzed reaction. Biochemistry 1989;28(19):7572-82
111. Gourley DG, Coggins JR, Isaacs NW, et al. Crystallization of a type II dehydroquinase from Mycobacterium tuberculosis. J Mol Biol 1994;241(3):488-91
112. Michel G, Roszak AW, Sauve V, et al. Structures of shikimate dehydrogenase AroE and its Paralog YdiB. A common structural framework for different activities. J Biol Chem 2003;278(21):19463-72
113. Ye S, Von Delft F, Brooun A, et al. The crystal structure of shikimate dehydrogenase (AroE) reveals a unique NADPH binding mode. J Bacteriol 2003;185(14):4144-51
114. Baillie AC, Corbett JR, Dowsett JR, et al. Inhibitors of shikimate dehydrogenase as potential herbicides. Biochem J 1972;126(3):21P
115. Steinrucken HC, Amrhein N. The herbicide glyphosate is a potent inhibitor of 5-enolpyruvyl-shikimic acid-3-phosphate synthase. Biochem Biophys Res Commun 1980;94(4):1207-12
116. Herrmann KM, Weaver LM. The shikimate pathway. Ann Rev Plant Physiol Plant Mol Biol 1999;50:473-503
117. Dias MV, Ely F, Canduri F, et al. Crystallization and preliminary X-ray crystallographic analysis of chorismate synthase from Mycobacterium tuberculosis. Acta Crystallogr D Biol Crystallogr 2004;60(Pt 11):2003-5